IDYA icon

IDEAYA Biosciences

25.35 USD
+0.51
2.05%
At close Jul 30, 4:00 PM EDT
After hours
25.00
-0.35
1.38%
1 day
2.05%
5 days
6.38%
1 month
20.60%
3 months
25.93%
6 months
6.16%
Year to date
0.76%
1 year
-40.00%
5 years
124.34%
10 years
126.54%
 

About: IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Employees: 131

0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

144% more call options, than puts

Call options by funds: $1.43M | Put options by funds: $585K

113% more repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 48

4% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 26

0.79% more ownership

Funds ownership: 106.37% [Q4 2024] → 107.17% (+0.79%) [Q1 2025]

0% more funds holding

Funds holding: 203 [Q4 2024] → 203 (+0) [Q1 2025]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 3 (-1) [Q1 2025]

35% less capital invested

Capital invested by funds: $2.36B [Q4 2024] → $1.54B (-$821M) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$30
18%
upside
Avg. target
$49
92%
upside
High target
$72
184%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
JP Morgan
Anupam Rama
184%upside
$72
Overweight
Maintained
28 Jul 2025
RBC Capital
Leonid Timashev
18%upside
$30
Outperform
Maintained
9 Jul 2025
Wells Fargo
Eva Fortea Verdejo
74%upside
$44
Overweight
Initiated
26 Jun 2025

Financial journalist opinion

Based on 4 articles about IDYA published over the past 30 days

Neutral
PRNewsWire
6 days ago
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma
The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohorts Darovasertib has received U.S. FDA Breakthrough Therapy Designation for use in neoadjuvant uveal melanoma for subjects requiring enucleation Initiated a multi-site, global randomized Phase 3 neoadjuvant registrational trial in primary uveal melanoma (OptimUM-10) in Q3 2025 SOUTH SAN FRANCISCO, Calif. , July 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced that results from a multi-site global Phase 2 study of neoadjuvant darovasertib in primary uveal melanoma was accepted for a Proffered Paper oral presentation at the 2025 European Society of Medical Oncology (ESMO) meeting, taking place on October 17-21 in Berlin, Germany.
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma
Neutral
PRNewsWire
1 week ago
IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
SOUTH SAN FRANCISCO, Calif. , July 23, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it will host an in-person and virtual R&D Day on September 8, 2025 from 8:00am to 10:00am ET in New York City to present multiple clinical data updates across the pipeline and highlight the next key drivers of growth and upcoming milestones.
IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
Neutral
PRNewsWire
1 week ago
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1 trial Data will include patients from the dose escalation and at multiple expansion doses U.S. Phase 1 trial of IDE849 in SCLC patients initiated in 3Q 2025 JIANGSU, China and SOUTH SAN FRANCISCO, Calif. , July 22, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Jiangsu Hengrui Pharmaceuticals Co., Ltd.
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
Neutral
PRNewsWire
1 week ago
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
SOUTH SAN FRANCISCO, Calif. , July 21, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations event.
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
Neutral
PRNewsWire
1 month ago
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , June 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 26, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 95,600 shares of the Company's common stock to a newly hired employee.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Neutral
PRNewsWire
1 month ago
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
SOUTH SAN FRANCISCO, Calif. , June 2, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
Neutral
PRNewsWire
2 months ago
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , May 30, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 29, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 664,600 shares of the Company's common stock to nine newly hired employees.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Neutral
Seeking Alpha
2 months ago
Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849
Ideaya Biosciences, Inc. is advancing darovasertib in a phase 2/3 trial for HLA-A2-negative metastatic uveal melanoma patients, with mPFS data expected by end of 2025. Ideaya plans a phase 3 study of darovasertib as a neoadjuvant for uveal melanoma, starting in the first half of 2025. IDE849 is an ADC targeting DLL3 in SCLC and NETs, This program has two catalysts: phase 1 data in Q3 2025 and a new study in H2 2025.
Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849
Neutral
PRNewsWire
2 months ago
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM trial; targeting median PFS results by YE 2025 to enable potential accelerated approval filing Successful FDA Type D meeting completed to finalize darovasertib Ph3 registrational trial design and received U.S. FDA Breakthrough Therapy Designation in neoadjuvant UM Targeting three darovasertib program clinical data updates at medical conferences in 2025, including 1L MUM mOS results in >40 patients and neoadjuvant UM data in >90 patients IDE849 (DLL3 TOP1 ADC) Phase 1 initiated in U.S., and partner Hengrui targeting clinical data update in over 40 SCLC patients at a medical conference in Q3 2025 Oral presentation of potential best-in-class Phase 1 WRN inhibitor IDE275 at AACR 2025 Three additional IND-filings targeted in 2025: PRMT5, B7H3/PTK7 ADC, and KAT6/7 SOUTH SAN FRANCISCO, Calif. , May 6, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the first quarter that ended March 31, 2025.
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Neutral
PRNewsWire
2 months ago
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
Targeting to evaluate IDE849 (SHR-4849) in SCLC, NETs, and other DLL3-upregulated solid tumors, and in combination with IDE161/PARG to potentially enhance durability Targeting to present clinical data of over 40 SCLC patients, including the dose escalation and expansion, from partner Hengrui at medical conference in Q3 2025 SOUTH SAN FRANCISCO, Calif. , May 6, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE849 (SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC) program, in solid tumors.
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
Charts implemented using Lightweight Charts™